The first pa­tient has been treat­ed un­der the con­tro­ver­sial 'right to try' law

A pa­tient di­ag­nosed with an ag­gres­sive form of brain can­cer be­came the first per­son in the US to ac­cess an ex­per­i­men­tal treat­ment un­der Right to Try. Signed in­to law by Pres­i­dent Don­ald Trump in May 2018, it has been tout­ed as a new way to help peo­ple with ter­mi­nal ill­ness­es and few op­tions, al­though un­til now, no pa­tients had ever used it.

ERC-USA and the Uni­ver­si­ty of Cal­i­for­nia, Irvine ini­ti­at­ed treat­ment with the com­pa­ny’s in­ves­ti­ga­tion­al com­pound ERC-1671 — known as Glio­vac in Eu­rope — and which is in Phase 2 clin­i­cal tri­als in the US. The pa­tient’s treat­ment with ERC-1671 be­gan at the uni­ver­si­ty in late No­vem­ber 2018.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.